|
||||||
| Home |
| Find a Clinical Trial |
| Clinical Trial FAQs |
| About Informed Consent |
| Clinical Trials Glossary |
| Medical Research Areas |
| Clinical Trial Resources |
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
 |
|
|
|
|||
|
Novartis Clinical
Trials provides information about research studies recruiting
within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S. |
|
|
Find a Clinical Trial
Lymphoma
Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin's lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin's lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin's lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin's and non-Hodgkin's lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer. [Source: www.cancer.gov]
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Mantle Cell Lymphoma Study - N2201
The purpose of this open-label, single-arm phase II study is to evaluate the safety and efficacy of a Novartis investigational drug in people with mantle cell lymphoma where the disease has progressed despite standard therapy. An "investigational drug" is a drug that is being clinically tested and is not approved for sale or use in the United States by the Food and Drug Administration (FDA), for the indication in which it is being studied.
Trial phase: Phase 2 Participation Duration: Participants will be required to visit the study center twice per month during the first 3 months and, then every 28 days until treatment with the study drug is finished. Protocol Number: CRAD001N2201 Hodgkin's Lymphoma (Refractory/Relapsed) Study - NUS65
The purpose of this open-label, single-arm phase II clinical trial is to assess if a Novartis investigational drug is effective at slowing the progression of cancer in patients with refractory or relapsed classical Hodgkin's lymphoma. An "investigational drug" is a drug that is being clinically tested and is not approved for sale or use in the United States by the Food and Drug Administration (FDA), for the indication in which it is being studied.
Trial phase: Phase 2 Participation Duration: Participants will be asked to visit the study center once every 14 days during the first three months of treatment, and then once every 28 days until treatment is complete. Protocol Number: CRAD001NUS65
Diffuse Large B-Cell Lymphoma (DLBCL) Study - N2301
A randomized, double-blind, placebo-controlled, multicenter research study that will test how safe and effective a Novartis investigational drug is at slowing or preventing the recurrence of diffuse large B-cell lymphoma compared to placebo. An "investigational drug" is a drug that is being clinically tested and is not approved for sale or use in the United States by the Food and Drug Administration (FDA), for the indication in which it is being studied.
Trial phase: Phase 3 Participation Duration: The planned treatment duration for this trial is 1 year, and post treatment assessments will be required for a minimum of 5 years. Protocol Number: CRAD001N2301 |